glp 1 drugs for alcohol use disorder GLP-1 receptor agonists are promising but unproven treatments and substance disorders GLP-1 Receptor Agonists and Research

Bias in meta-analysis detected by a simple, graphical test

Real-world evidence from a registry of 3865 T2DM patients showed that those treated with GLP-1 agonists had a 28% lower incidence of heart failure hospitalization compared to other glucose-lowering therapies, with the benefit being most pronounced in patients with subclinical diabetic cardiomyopathy detected by elevated NT-proBNP levels [83]

Mean body weight changes across the groups at the end of 32 weeks were: CagriSema: 15.6% Semaglutide alone: 5.1% Cagrilinitide alone: 8.1% [43] Side effects included nausea (29% of patients), diarrhea (16%) and vomiting (10%) in CagriSema treated patients

This is consistent with patient reports, which are generally more positive about mental health benefits for Zepbound (tirzepatide) than for Wegovy (semaglutide)

However, some people have less side effects with Trulicity than Ozempic